vs
Side-by-side financial comparison of Neuphoria Therapeutics Inc. (NEUP) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
Neuphoria Therapeutics Inc. is the larger business by last-quarter revenue ($15.0M vs $12.5M, roughly 1.2× SOLESENCE, INC.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs 1.3%, a 73.8% gap on every dollar of revenue.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
NEUP vs SLSN — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.5M |
| Net Profit | $11.3M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | 79.8% | 1.5% |
| Net Margin | 75.1% | 1.3% |
| Revenue YoY | — | -0.7% |
| Net Profit YoY | — | 129.2% |
| EPS (diluted) | $6.55 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $20.4M | ||
| Q1 25 | $15.0M | $14.6M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $16.9M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | $163.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | $11.3M | $80.0K | ||
| Q4 24 | — | $-559.0K | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | — | $856.0K | ||
| Q1 24 | — | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | -5.4% | ||
| Q2 25 | — | 9.4% | ||
| Q1 25 | 79.8% | 1.8% | ||
| Q4 24 | — | -1.8% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 11.3% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | 75.1% | 0.5% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 18.1% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | $6.55 | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.0M | $17.6M |
| Total Assets | $30.7M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $429.0K | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | $17.0M | $1.8M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $17.2M | ||
| Q2 25 | — | $18.2M | ||
| Q1 25 | $26.0M | $15.2M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | — | $15.2M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | $50.1M | ||
| Q3 25 | — | $54.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | $30.7M | $57.0M | ||
| Q4 24 | — | $50.0M | ||
| Q3 24 | — | $48.0M | ||
| Q2 24 | — | $40.8M | ||
| Q1 24 | — | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.5M | $1.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.02× | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-654.0K | ||
| Q1 25 | $11.5M | $-7.2M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | — | $-565.0K | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-404.0K | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.2% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | -8.0% | ||
| Q1 24 | — | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 20.6% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | 1.02× | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
